1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 57 pages

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016’, provides an overview of the Herpes Labialis (Oral Herpes) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes)
- The report reviews pipeline therapeutics for Herpes Labialis (Oral Herpes) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Herpes Labialis (Oral Herpes) therapeutics and enlists all their major and minor projects
- The report assesses Herpes Labialis (Oral Herpes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Herpes Labialis (Oral Herpes)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Labialis (Oral Herpes) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 8
Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 9
Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 10
Herpes Labialis (Oral Herpes) - Therapeutics under Investigation by Universities/Institutes 11
Herpes Labialis (Oral Herpes) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Herpes Labialis (Oral Herpes) - Products under Development by Companies 15
Herpes Labialis (Oral Herpes) - Products under Investigation by Universities/Institutes 16
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 17
Beech Tree Labs, Inc. 17
Foamix Pharmaceuticals Ltd. 18
Mymetics Corporation 19
NanoViricides, Inc. 20
Onxeo SA 21
Shulov Innovative Science Ltd. 22
TGV-Laboratories 23
Vironova AB 24
Herpes Labialis (Oral Herpes) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
acyclovir - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
acyclovir - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Aspidasept - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
B-220 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
BTL-TMLHSV - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
herpes simplex virus [type 1, 2] vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
herpes simplex virus [type 1, 2] vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Small molecule for Cold Sores - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Teg-379 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
ZEP-3 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 45
Herpes Labialis (Oral Herpes) - Dormant Projects 48
Herpes Labialis (Oral Herpes) - Discontinued Products 49
Herpes Labialis (Oral Herpes) - Product Development Milestones 50
Featured News and Press Releases 50
Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada 50
Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent 50
Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants 51
May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium 51
Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis 52
Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial 53
Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig 53
May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier 53
Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure 54
Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2016 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H1 2016 17
Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 18
Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H1 2016 19
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H1 2016 20
Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H1 2016 21
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd., H1 2016 22
Herpes Labialis (Oral Herpes) - Pipeline by TGV-Laboratories, H1 2016 23
Herpes Labialis (Oral Herpes) - Pipeline by Vironova AB, H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H1 2016 45
Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2016 48
Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2016 49

List of Figures
Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2016 8
Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Targets, H1 2016 26
Number of Products by Stage and Targets, H1 2016 26
Number of Products by Mechanism of Actions, H1 2016 28
Number of Products by Stage and Mechanism of Actions, H1 2016 28
Number of Products by Routes of Administration, H1 2016 30
Number of Products by Stage and Routes of Administration, H1 2016 30
Number of Products by Molecule Types, H1 2016 32
Number of Products by Stage and Molecule Types, H1 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.